Academic Journal
View in EDS
PDF Full Text
HTML Full Text

Author Correction: Direct and high throughput (HT) interactions on the ribosomal surface by iRIA

Bibliographic Details
Title: Author Correction: Direct and high throughput (HT) interactions on the ribosomal surface by iRIA
Authors: Elisa Pesce, Claudia Minici, Jochen Baßler, Ed Hurt, Massimo Degano, Piera Calamita, Stefano Biffo
Source: Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
Publisher Information: Nature Portfolio, 2023.
Publication Year: 2023
Collection: LCC:Medicine
LCC:Science
Subject Terms: Medicine, Science
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-023-28876-7
Access URL: https://doaj.org/article/f52f929a627d42f39e9074a05ba066f6
Accession Number: edsdoj.f52f929a627d42f39e9074a05ba066f6
Database: Directory of Open Access Journals
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
    Url: https://content.ebscohost.com/cds/retrieve?content=AQICAHjPtM4BHU3ZchRwgzYmadcigk49r9CVlbU7V5F6lgH7WwEtj9abniBF5VdmLkFZPA6DAAAA4jCB3wYJKoZIhvcNAQcGoIHRMIHOAgEAMIHIBgkqhkiG9w0BBwEwHgYJYIZIAWUDBAEuMBEEDCtOpkxMVr3LuXoJWwIBEICBmivFEDlSU_oH8IQcsq5Vsgi1taW7ZTUDn-dmUQu3h-TJ5lEFqOqiHczk5DUVDyom8uJzNlBooa2CHI_KN_rwciQ5VlS3Lc1t5UcOeRxMjTnPsb9SKoshNTRkoxhTP7hHpj01kg5NKGuyPh-fApl9WbGByWVZzew5ymhXp2MgCL4Bct92khZLYaP03M1R6nFDzcsvwz062NT0vSk=
Text:
  Availability: 1
  Value: <anid>AN0162057377;[fkqs]23feb.23;2023Feb27.03:49;v2.2.500</anid> <title id="AN0162057377-1">Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation </title> <p>The combination of noradrenergic (reboxetine) plus antimuscarinic (oxybutynin) drugs (reb-oxy) reduced obstructive sleep apnea (OSA) severity but no data are available on its effects on cardiac autonomic modulation. We sought to evaluate the impact of 1-week reb-oxy treatment on cardiovascular autonomic control in OSA patients. OSA patients were randomized to a double-blind, crossover trial comparing 4 mg reboxetine plus 5 mg oxybutynin to a placebo for OSA treatment. Heart rate (HR) variability (HRV), ambulatory blood pressure (BP) monitoring (ABPM) over 24 h baseline and after treatment were performed. Baroreflex sensitivity was tested over beat-to-beat BP recordings. 16 subjects with (median [interquartile range]) age 57 [51–61] years and body mass index 30 [26–36]kg/m<sup>2</sup> completed the study. The median nocturnal HR was 65 [60–69] bpm at baseline and increased to 69 [64–77] bpm on reb-oxy vs 66 [59–70] bpm on placebo (p = 0.02). The mean 24 h HR from ABPM was not different among treatment groups. Reb-oxy administration was not associated with any modification in HRV or BP. Reb-oxy increased the baroreflex sensitivity and did not induce orthostatic hypotension. In conclusion, administration of reb-oxy did not induce clinically relevant sympathetic overactivity over 1-week and, together with a reduction in OSA severity, it improved the baroreflex function.</p> <p>These authors contributed equally: Gianfranco Parati and Carolina Lombardi.</p> <hd id="AN0162057377-2">Introduction</hd> <p>Obstructive sleep apnea (OSA) is one of the most common sleep disorders affecting one-third of the population aged 30–70 years in Europe[<reflink idref="bib1" id="ref1">1</reflink>]. The repetitive collapse of the pharyngeal airway characteristic of OSA leads to intermittent oxygen desaturations and sleep fragmentation with downstream consequences, including an increased risk of cardiovascular disease, daytime sleepiness, and sympathetic nervous system over-activity[<reflink idref="bib2" id="ref2">2</reflink>],[<reflink idref="bib3" id="ref3">3</reflink>]. Intermittent hypoxemia and arousals from sleep activate the sympathetic nervous system, being them the major contributors to the blood pressure (BP) and heart rate (HR) elevation, together with the release of inflammatory mediators[<reflink idref="bib2" id="ref4">2</reflink>],[<reflink idref="bib4" id="ref5">4</reflink>]. Thus, untreated OSA may lead to cardiovascular, neurocognitive, metabolic, and daytime functional consequences over time, resulting in increased morbidity and mortality[<reflink idref="bib5" id="ref6">5</reflink>].</p> <p>In the last 40 years, the gold standard for OSA treatment has been nocturnal ventilation through continuous positive airway pressure (CPAP), which acts to pneumatically splint the pharynx open. If regularly employed, CPAP therapy might reduce cardiovascular risk and overall mortality rate[<reflink idref="bib6" id="ref7">6</reflink>],[<reflink idref="bib7" id="ref8">7</reflink>], partially by attenuating sympathetic over-activity[<reflink idref="bib8" id="ref9">8</reflink>],[<reflink idref="bib9" id="ref10">9</reflink>] and improving arterial baroreflex sensitivity, depressed by OSA[<reflink idref="bib10" id="ref11">10</reflink>]–[<reflink idref="bib12" id="ref12">12</reflink>]. Although OSA is effectively alleviated by this treatment, CPAP is poorly tolerated by many patients, with a consequent very low adherence[<reflink idref="bib13" id="ref13">13</reflink>],[<reflink idref="bib14" id="ref14">14</reflink>]. Hence, there is an urgent need for alternative interventions that are safe and well-tolerated[<reflink idref="bib15" id="ref15">15</reflink>]–[<reflink idref="bib17" id="ref16">17</reflink>].</p> <p>Reduced pharyngeal dilator muscle tone and responsiveness during sleep are key contributors to OSA pathogenesis[<reflink idref="bib18" id="ref17">18</reflink>],[<reflink idref="bib19" id="ref18">19</reflink>]. Responsible for the latter is a loss of noradrenergic drive and muscarinic inhibition to the upper airway muscles[<reflink idref="bib20" id="ref19">20</reflink>],[<reflink idref="bib21" id="ref20">21</reflink>]. In the last years, these findings have stimulated research on pharmacological solutions aimed at improving neural control of pharyngeal muscle tone. In such a context, pharmacotherapy for OSA is moving its first steps with promising results provided by single-night studies[<reflink idref="bib17" id="ref21">17</reflink>],[<reflink idref="bib22" id="ref22">22</reflink>]. We have recently performed a study aimed at expanding the knowledge on these pharmacological possibilities by conducting a randomized controlled trial to evaluate for the first time the effectiveness of the combination of reboxetine (a noradrenaline reuptake inhibitor agent) and oxybutynin (an antimuscarinic compound), administered over a 1-week period, versus placebo on patients with moderate-to-severe OSA with promising results[<reflink idref="bib23" id="ref23">23</reflink>].</p> <p>As known, noradrenaline is the main neurotransmitter of the sympathetic nervous system and muscarinic receptors are responsible for the vagal activity. Thus, a pending issue, not yet explored, is the possibility that the administration of noradrenergic reboxetine together with antimuscarinic oxybutynin might negatively affect the autonomic control of circulation[<reflink idref="bib24" id="ref24">24</reflink>],[<reflink idref="bib25" id="ref25">25</reflink>]. On the other hand, the substantial decrease of the apnea-hypopnea index (AHI) with the resulting improvement of nocturnal hypoxemia induced by reb-oxy, might be also associated with beneficial effects on sympathetic over-activity, thus counterbalancing the direct sympathetic stimulation of these noradrenergic and antimuscarinic drugs.</p> <p>The sympathetic and parasympathetic cardiovascular modulation can be assessed with direct measurements, or thanks to non-invasive reliable tools such as BP by 24 h ambulatory monitoring (ABPM), HR variability (HRV), and baroreceptor sensitivity (BRS)[<reflink idref="bib24" id="ref26">24</reflink>],[<reflink idref="bib26" id="ref27">26</reflink>]–[<reflink idref="bib28" id="ref28">28</reflink>].</p> <p>In order to assess the effect of reboxetine plus oxybutynin (reb-oxy) on cardiovascular autonomic modulation in OSA patients, we performed 24 h ABPM and estimated BRS and HRV after 1-week of treatment in the frame of our randomized controlled cross-over trial. The outcomes were evaluated as the change from baseline during the week of reb-oxy administration and compared to placebo.</p> <hd id="AN0162057377-3">Methods</hd> <p></p> <hd id="AN0162057377-4">Patients and study design</hd> <p>We performed a randomized, double-blind, placebo-controlled, cross-over, single-center study of the combination of reb-oxy in adults with OSA documented by polysomnography (PSG). Participants were enrolled from July 2020 to October 2020 through our sleep clinic (Istituto Auxologico Italiano, Milan, Italy) and the trial ended when the previously calculated sample size of 16 patients was reached. Participants were randomized (1:1 ratio) to first receive a 4 mg reboxetine plus 5 mg oxybutynin or a matching placebo, and then to switch to the other treatment arm after a washout of 7–10 days. Study participants matching eligibility criteria performed a one-night inpatient PSG test, which served as the baseline measure for AHI. Subjects started taking the study drug the day after the baseline PSG, immediately before bedtime, and continued for 7 days in total. On the final dosing night of each week, participants performed in-lab PSG. The study was approved by the Ethics Committee on 18/02/2020 (approval n. 2020_02_18_03) and by the Italian drug agency AIFA (Agenzia Italiana del Farmaco) on 22/04/2020 (EudraCT n 2019-004917-15) and all methods were performed in accordance with the guidelines and regulations. Informed consent in writing was obtained from all study participants. The study was first registered at ClinicalTrials.gov (NCT04449133) on 26/06/2020.</p> <hd id="AN0162057377-5">Measurements</hd> <p></p> <hd id="AN0162057377-6">Overnight in-lab polysomnography</hd> <p>PSG recording and data interpretation was performed in accordance with the American Academy of Sleep Medicine (AASM) scoring manual[<reflink idref="bib29" id="ref29">29</reflink>]. All studies were scored by the same specialized sleep clinician, blinded to treatment assignment, according to AASM scoring criteria[<reflink idref="bib30" id="ref30">30</reflink>].</p> <hd id="AN0162057377-7">Heart rate variability</hd> <p>The beat-by-beat series of R-R intervals were extracted from 1 ECG channel of each PSG through a derivative-and-threshold algorithm, selecting a segment of at least 10-min duration without respiratory events in the supine position during non-REM stage 2 (N2) sleep for the HRV analysis. Premature beats were visually identified and manually removed, obtaining series of normal-to-normal intervals (NNI). Time-domain indexes of HRV were the root-mean-square of successive differences (RMSSD) and the percentage of beats with NNI value at least 50 ms longer or shorter than NNI of their preceding beat (pNN50)[<reflink idref="bib28" id="ref31">28</reflink>]. For the frequency-domain analysis, the NNI series was resampled evenly at 5 Hz linearly interpolating possibly missing beats. The Welch periodogram was estimated using 50% overlapped Hanning windows of 120 s length. The powers in the very-low-frequency (VLF, between 0.0025 and 0.04 Hz), low-frequency (LF, between 0.04 and 0.15 Hz), and high-frequency (HF, between 0.15 and 0.40 Hz) bands, as well as the LF/HF powers ratio, were obtained by integrating the periodogram[<reflink idref="bib28" id="ref32">28</reflink>]. The breathing rate was estimated from the fluctuations of QRS-complex amplitude of the ECG reflecting the respiratory movements of the thorax[<reflink idref="bib31" id="ref33">31</reflink>]. The series of the R peaks resampled at 5 Hz were high-pass filtered at 0.05 Hz to remove oscillations too long to be generated by respiratory movements; the Welch periodogram was calculated and the breathing rate measured as the frequency of the highest spectral peak.</p> <hd id="AN0162057377-8">Ambulatory blood pressure monitoring</hd> <p>ABPM was performed using a validated oscillometric device (TM2430; A&D Medical, Japan) to evaluate blood pressure (BP) changes for 24 h. Blood pressure was evaluated every 20 min during the day and every 30 min during the night. Day and night sub-periods were defined according to the personal logbook. 24 h, daytime and night-time average Systolic BP (SBP), Diastolic BP (DBP) and heart rate (HR), day and night SBP and DBP standard deviations (SD) were quantified to assess BP variability, SBP and DBP nocturnal falls, night/day ratios, average morning (7–11 a.m.) values and morning surge (defined as the difference between the lowest SBP or DBP value before the morning rise and the highest SBP or DBP value after awakening). The ABPM monitoring was assessed in the pre-screening visit at least 2 days before baseline PSG and between the 2nd and the 5th night of the two weeks of treatment to avoid disturbing the PSG night sleep.</p> <hd id="AN0162057377-9">Baroreflex function</hd> <p>ECG and non-invasive BP were measured by a Nexfin<sups>®</sups> device (BMEYE, Amsterdam, The Netherlands). Patients underwent measurements at rest, without coffee intake in the previous 3 h and at the same time of the day before the PSG. Recordings were performed in a silent room without speaking and without any disturbing elements for 10 min while patients were lying supine, and then for 10 min while they were standing. The beat-by-beat values of SBP and DBP, derived from the continuous BP, recordings, and NNI from the ECG lead, were interpolated evenly at 5 Hz for spectral analysis. The sensitivity of the baroreflex control of heart rate (BRS) was estimated by the sequence technique[<reflink idref="bib32" id="ref34">32</reflink>] (BRS<subs>SEQ</subs>), the transfer function technique (H<subs>LF</subs>)[<reflink idref="bib33" id="ref35">33</reflink>], and the spectral method (α<subs>LF</subs>)[<reflink idref="bib34" id="ref36">34</reflink>]. As to BRS<subs>SEQ</subs>, the beat-to-beat series were scanned in search of sequences of 3 or more consecutive heartbeats in which a progressive SBP increase was followed, with a lag of zero, one or two beats, by a progressive NNI lengthening or, vice versa, in which a progressive SBP reduction was followed by a progressive NNI shortening. The slope of the regression line between SBP and NNI values in each sequence was taken as a local BRS estimate. The local estimates were averaged over the supine and standing periods separately to obtain the final BRS<subs>SEQ</subs> values. As to the spectral and transfer function estimates, the SBP and NNI power spectra, and SBP-NNI cross-spectrum and coherency spectrum were calculated from the evenly resampled series at 5 Hz using 50% overlapped Hann data windows of 120s length. SBP and NNI powers were calculated over the LF band and the root square of the SBP/ NNI powers ratio evaluated only for spectral lines with squared coherence modulus > 0.3 provided the α<subs>LF</subs> estimate of BRS. The ratio between the SBP-NNI cross-spectrum and NNI spectrum was calculated considering again only spectral lines with squared coherence modulus > 0.3 and averaged over the LF band, providing the H<subs>LF</subs> estimate of BRS.</p> <p>The DBP power spectrum was similarly estimated by the Welch periodogram. The baroreflex resonance was quantified by integrating the DBP and SBP power spectra over the LF band (DBP<subs>LF</subs> and SBP<subs>LF</subs>). These indexes measure the power of the 10-s oscillations in arterial BP, which are considered a surrogate measure of sympathetic activity[<reflink idref="bib35" id="ref37">35</reflink>].</p> <p>For each index, the difference (delta Δ) between supine position and standing was also calculated.</p> <hd id="AN0162057377-10">Statistical analysis</hd> <p>Categorical data were summarized by proportions, while continuous data by median [interquartile range] values. Percent changes in study variables from baseline after 1-week of placebo and after 1-week of reb-oxy were compared as continuous variables by using a two-tailed Wilcoxon matched-pairs signed-rank test. The effect of the drug combination on the cardiovascular autonomic nervous system reported here was a prespecified exploratory outcome, while the primary outcome was AHI change as reported in our previous publication[<reflink idref="bib23" id="ref38">23</reflink>]. According to study design, a sample size of 16 subjects was powered to detect an AHI reduction with Reb-Oxy than placebo (alpha 5%, power 80%), plus a ≈ 20% dropout{Perger, 2022 #223}.</p> <p>A <emph>p</emph>-value of <0·05 was considered statistically significant. Statistical analyses were performed using Statistical Analysis Software (SAS Cary, NC, USA).</p> <hd id="AN0162057377-11">Results</hd> <p>The anthropometric and clinical characteristics of the 16 participants are presented in Table 1. None had beta-blockers as chronic therapy. No serious adverse events occurred. The main sleep and OSA severity metrics are summarized in Table 2. Other results of this trial have been previously published[<reflink idref="bib23" id="ref39">23</reflink>].</p> <p>Table 1 Characteristics of the enrolled population (total number of subjects = 16).</p> <p> <ephtml> <table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2"><p>General characteristics</p></td></tr><tr><td align="left"><p> Age, years</p></td><td align="left"><p>57 [51–61]</p></td></tr><tr><td align="left"><p> Male</p></td><td align="left"><p>14 (88%)</p></td></tr><tr><td align="left"><p> Body mass index Kg/m<sup>2</sup></p></td><td align="left"><p>30 [26–36]</p></td></tr><tr><td align="left"><p> Current smokers</p></td><td align="left"><p>8 (50%)</p></td></tr><tr><td align="left" colspan="2"><p>Risk factors and comorbidities</p></td></tr><tr><td align="left"><p> Hypertension</p></td><td align="left"><p>7 (44%)</p></td></tr><tr><td align="left"><p> Diabetes</p></td><td align="left"><p>1 (6%)</p></td></tr><tr><td align="left"><p> Dyslipidemia</p></td><td align="left"><p>7 (44%)</p></td></tr><tr><td align="left"><p> Hypothyroidism</p></td><td align="left"><p>3 (19%)</p></td></tr><tr><td align="left"><p> Rheumatoid arthritis</p></td><td align="left"><p>1 (6%)</p></td></tr><tr><td align="left" colspan="2"><p>Pharmacological treatments</p></td></tr><tr><td align="left"><p> ACE-I/ARB</p></td><td align="left"><p>6 (35%)</p></td></tr><tr><td align="left"><p> Calcium channel blocker</p></td><td align="left"><p>1 (6%)</p></td></tr><tr><td align="left"><p> Diuretics</p></td><td align="left"><p>1 (6%)</p></td></tr><tr><td align="left"><p> Antilipidemics</p></td><td align="left"><p>4 (25%)</p></td></tr><tr><td align="left"><p> Antidiabetics</p></td><td align="left"><p>1 (6%)</p></td></tr><tr><td align="left"><p> Antithrombotics</p></td><td align="left"><p>2 (13%)</p></td></tr></tbody></table> </ephtml> </p> <p>ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; Data are presented as absolute number (%) or median [interquartile range].</p> <p>Table 2 Obstructive Sleep Apnea severity parameters (some reported from previous study[<reflink idref="bib23" id="ref40">23</reflink>]), main sleep characteristics, and heart rate variability (HRV) at baseline, on placebo, and on active drugs combination (n = 16); HRV was assessed from EKG of nocturnal PSG during N2 sleep at baseline, on placebo, and on active drugs combination.</p> <p> <ephtml> <table frame="hsides" rules="groups"><thead><tr><th align="left" /><th align="left"><p>Baseline</p></th><th align="left"><p>Placebo</p></th><th align="left"><p>Reb-Oxy</p></th><th align="left"><p><italic>p</italic>-value</p></th></tr></thead><tbody><tr><td align="left" colspan="5"><p>Full night PSG</p></td></tr><tr><td align="left"><p> AHI total, events/h</p></td><td align="left"><p>48.7 [34.8–56.6]</p></td><td align="left"><p>38.7 [29.0–47.8]</p></td><td align="left"><p>18.0 [12.5–21.4]</p></td><td char="." align="char"><p> < 0.01</p></td></tr><tr><td align="left"><p> Hypoxic burden, %min/h</p></td><td align="left"><p>90.8 [69.5–154]</p></td><td align="left"><p>75.5 [68.1–168.0]</p></td><td align="left"><p>39.7 [25.4–55.3]</p></td><td char="." align="char"><p> < 0.01</p></td></tr><tr><td align="left"><p> ODI 3%, events/h</p></td><td align="left"><p>42.7 [32.3–53.0]</p></td><td align="left"><p>36.8 [23.8–43.2]</p></td><td align="left"><p>31.4 [19.1–37.7]</p></td><td char="." align="char"><p>0.03</p></td></tr><tr><td align="left"><p> Total sleep time, min</p></td><td align="left"><p>329.5 [301.0–368.8]</p></td><td align="left"><p>323.5 [274.4–351.4]</p></td><td align="left"><p>321.8 [283.0–362.9]</p></td><td char="." align="char"><p>0.50</p></td></tr><tr><td align="left"><p> PLM index, events/h</p></td><td align="left"><p>0.0 [0.0–2.8]</p></td><td align="left"><p>0.0 [0.0–2.8]</p></td><td align="left"><p>0.5 [0.0–2.8]</p></td><td char="." align="char"><p>0.81</p></td></tr><tr><td align="left"><p> HR, bpm</p></td><td align="left"><p>65 [59.5–69]</p></td><td align="left"><p>65.6 [58.8–69.55]</p></td><td align="left"><p>69.35 [63.8–76.75]</p></td><td char="." align="char"><p>0.02</p></td></tr><tr><td align="left" colspan="5"><p>HRV in N2 phase</p></td></tr><tr><td align="left"><p> RMSSD, ms<sup>2</sup></p></td><td align="left"><p>40.4 [17.5–51.6]</p></td><td align="left"><p>24.7 [17.6–43.1]</p></td><td align="left"><p>32.4 [25.4–51.6]</p></td><td char="." align="char"><p>0.38</p></td></tr><tr><td align="left"><p> pNN50</p></td><td align="left"><p>0.18 [0.01–0.32]</p></td><td align="left"><p>0.02 [0.001–0.18]</p></td><td align="left"><p>0.10 [0.03–0.35]</p></td><td char="." align="char"><p>0.40</p></td></tr><tr><td align="left"><p> HF, ms<sup>2</sup></p></td><td align="left"><p>300.0 [90.7–748.4]</p></td><td align="left"><p>189.7 [85.6–527.2]</p></td><td align="left"><p>328.8 [181.5–887.9]</p></td><td char="." align="char"><p>0.53</p></td></tr><tr><td align="left"><p> LF, ms<sup>2</sup></p></td><td align="left"><p>370.2 [136.9–1021.4]</p></td><td align="left"><p>222.8 [159.1–1099.7]</p></td><td align="left"><p>371.47 [227.8–614.94]</p></td><td char="." align="char"><p>0.38</p></td></tr><tr><td align="left"><p> LF/HF</p></td><td align="left"><p>2.4 [0.9–3.9]</p></td><td align="left"><p>1.3 [0.9–2.4]</p></td><td align="left"><p>1.1 [0.6–1.7]</p></td><td char="." align="char"><p>0.46</p></td></tr><tr><td align="left"><p> VLF, ms<sup>2</sup></p></td><td align="left"><p>680.6 [341.1–2879.1]</p></td><td align="left"><p>504.4 [232.3–2095.3]</p></td><td align="left"><p>659.4 [434.4–885.6]</p></td><td char="." align="char"><p>0.25</p></td></tr></tbody></table> </ephtml> </p> <p>reb–oxy = reboxetine plus oxybutynin; AHI = apnea–hypopnea index; ODI = oxygen desaturation index; PLM = periodic legs movements; HR = heart rate; SD = standard deviation; RMSSD = Root Mean Square of the Successive Differences; pNN50 = the proportion of number of pairs of successive NN (R-R) intervals that differ by more than 50 ms; HF = high frequency; LF = low frequency; VLF = very low frequency. Data are presented as median [interquartile] % changes are expressed as the median of percentage change. <emph>P</emph> values compare placebo versus reb-oxy. <emph>P</emph>-values are calculated by comparing the percentage changes from baseline observed in the placebo versus reb-oxy.</p> <hd id="AN0162057377-12">Heart rate and blood pressure</hd> <p>Median nocturnal heart rate (HR) during the PSG increased from 65 [60–69] bpm at baseline to 69 [64–77] bpm on reb-oxy and to 66 [59–70] bpm on placebo (<emph>p</emph>=0.02 for reb-oxy versus placebo) (Table 2). However, 24 h HR measured by ABPM was not significantly different between treatment groups, as shown in Table 3.</p> <p>Table 3 Ambulatory blood pressure data at baseline, on placebo, and on reb-oxy drug combination (n = 16).</p> <p> <ephtml> <table frame="hsides" rules="groups"><thead><tr><th align="left" /><th align="left"><p>Baseline</p></th><th align="left"><p>Placebo</p></th><th align="left"><p>Reb-Oxy</p></th><th align="left"><p><italic>p</italic>-value</p></th></tr></thead><tbody><tr><td align="left" colspan="5"><p>BP values</p></td></tr><tr><td align="left"><p> 24 h DBP, mmHg</p></td><td align="left"><p>83.0 [76.3–87.8]</p></td><td align="left"><p>83.0 [75.3–85.7]</p></td><td align="left"><p>79.6 [75.6–89.5]</p></td><td char="." align="char"><p>0.68</p></td></tr><tr><td align="left"><p> 24 h SBP<bold>,</bold> mmHg</p></td><td align="left"><p>131.6 [122.1–140.3]</p></td><td align="left"><p>129.5 [121.0–133.1]</p></td><td align="left"><p>121.5 [115.4–140.9]</p></td><td char="." align="char"><p>0.72</p></td></tr><tr><td align="left"><p> 24 h HR, bpm</p></td><td align="left"><p>78.0 [71.7–90.4]</p></td><td align="left"><p>80.2 [71.5–87.6]</p></td><td align="left"><p>79.1 [69–86.6]</p></td><td char="." align="char"><p>0.60</p></td></tr><tr><td align="left"><p> Day-time DBP, mmHg</p></td><td align="left"><p>86.8 [82.2–92.6]</p></td><td align="left"><p>85.78 [80.4–88.3]</p></td><td align="left"><p>82.18 [78.6–94.7]</p></td><td char="." align="char"><p>0.86</p></td></tr><tr><td align="left"><p> Day-time SBP, mmHg</p></td><td align="left"><p>138.7 [129.9–145.1]</p></td><td align="left"><p>133.0 [125.1–138.1]</p></td><td align="left"><p>125.0 [117.3–144.3]</p></td><td char="." align="char"><p>0.46</p></td></tr><tr><td align="left"><p> Night-time DBP, mmHg</p></td><td align="left"><p>71.8 [65.9–76.0]</p></td><td align="left"><p>70.7 [67.1–76.5]</p></td><td align="left"><p>69 [65.6–76.5]</p></td><td char="." align="char"><p>0.50</p></td></tr><tr><td align="left"><p> Night-Time SBP, mmHg</p></td><td align="left"><p>112.3 [106.1–124.2]</p></td><td align="left"><p>118.5 [108.6–126.2]</p></td><td align="left"><p>110.1 [107.6–132.3]</p></td><td char="." align="char"><p>0.28</p></td></tr><tr><td align="left" colspan="5"><p>BP variability</p></td></tr><tr><td align="left"><p> Morning surge DBP, mmHg</p></td><td align="left"><p>20.0 [15.5–40.0]</p></td><td align="left"><p>15.0 [6.5–34.5]</p></td><td align="left"><p>20.0 [10.0–33.0]</p></td><td char="." align="char"><p>0.60</p></td></tr><tr><td align="left"><p> Morning surge SBP, mmHg</p></td><td align="left"><p>48.0 [31.5–87.5]</p></td><td align="left"><p>33.0 [23.5–45.5]</p></td><td align="left"><p>32.0 [25.5–39.5]</p></td><td char="." align="char"><p>0.38</p></td></tr><tr><td align="left"><p> Day-time DBP SD mmHg</p></td><td align="left"><p>18.1 [11.5–20.6]</p></td><td align="left"><p>15.7 [12.7–18.3]</p></td><td align="left"><p>15.7 [11.7–19.1]</p></td><td char="." align="char"><p>0.90</p></td></tr><tr><td align="left"><p> Day-time SBP SD mmHg</p></td><td align="left"><p>17.9 [13.9–24.9]</p></td><td align="left"><p>16.9 [12.2–21.1]</p></td><td align="left"><p>17.2 [15.7–19.8]</p></td><td char="." align="char"><p>0.79</p></td></tr><tr><td align="left"><p> Night-time DBP SD mmHg</p></td><td align="left"><p>9.9 [7.9–13.2]</p></td><td align="left"><p>10.6 [8.4–13.7]</p></td><td align="left"><p>9.6 [9.3–10.9]</p></td><td char="." align="char"><p>0.23</p></td></tr><tr><td align="left"><p> Night-time SBP SD mmHg</p></td><td align="left"><p>12.1 [10.4–13.8]</p></td><td align="left"><p>13.2 [11.2–17.3]</p></td><td align="left"><p>12.3 [9.1–16.6]</p></td><td char="." align="char"><p>0.08</p></td></tr></tbody></table> </ephtml> </p> <p>reb–oxy = reboxetine plus oxybutynin; DBP = diastolic blood pressure; SBP = systolic blood pressure. Data are presented as median [interquartile range]. <emph>P</emph> values compare placebo versus reb-oxy. <emph>P</emph>-values are calculated by comparing the percent changes from baseline observed after placebo versus reb-oxy.</p> <p>Reb-oxy did not significantly modify 24 h, daytime, and night-time DBP and SBP (Table 3). Morning surge was not increased on reb-oxy as compared to placebo and BP variability was not significantly different during the day and the night between groups.</p> <p>Based on both time and frequency domain analyses, reb-oxy administration was not associated with any modifications in HRV (Table 2). The respiratory frequencies remained in the HF band in both groups.</p> <hd id="AN0162057377-13">Baroreflex sensitivity and resonance</hd> <p>Table 4 reports the estimates of baroreflex sensitivity and the measures of baroreflex resonance in BP spectral powers at baseline, after 1 week of placebo, and after 1 week of reb-oxy treatment. In the supine position, both the spectral and the transfer function estimates of baroreflex sensitivity were significantly greater after reb-oxy administration than on placebo. A similar effect was observed in standing position: both α<subs>LF</subs> and H<subs>LF</subs> increased more after treatment with reb-oxy than after the placebo treatment, the difference being significant for the spectral estimates. Figure 1 shows the corresponding percent changes from baseline recordings. The percent changes in α<subs>LF</subs> from supine to standing were similar on placebo (+ 49% [+ 32 to + 60] %) and on reb-oxy (+4 6% [+ 33 to + 66] %, <emph>p = </emph>0.58). The percent changes in H<subs>LF</subs> from supine to standing were similar on placebo (+ 49% [+ 30 to + 59] %) and on reb-oxy (+ 47% [+ 39 to + 69] %, <emph>p</emph> 0.42). When considering changes from baseline to treatment, no differences between placebo and reb-oxy were found for BRS<subs>SEQ</subs> (Table 1 and Figure 2). The percent changes in BRS<subs>SEQ</subs> from supine to standing were also similar between placebo (+ 36% [+ 26 to + 53] %) and reb-oxy (+ 54% [+ 34 to + 71] %, <emph>p</emph> 0.13).</p> <p>Table 4 Baroreflex sensitivity and resonance at baseline, on placebo, and on reb-oxy (n = 16).</p> <p> <ephtml> <table frame="hsides" rules="groups"><thead><tr><th align="left" /><th align="left"><p>Baseline</p></th><th align="left"><p>Placebo</p></th><th align="left"><p>Reb-Oxy</p></th><th align="left"><p><italic>p</italic>-value</p></th></tr></thead><tbody><tr><td align="left" colspan="5"><p>BRS ms/mmHg</p></td></tr><tr><td align="left"><p> α<sub>LF</sub> supine</p></td><td align="left"><p>5.3 [3.8–8.6]</p></td><td align="left"><p>6.0 [4.2–8.8]</p></td><td align="left"><p>9.3 [7.8–10.8]</p></td><td char="." align="char"><p>0.02</p></td></tr><tr><td align="left"><p> α<sub>LF</sub> standing</p></td><td align="left"><p>2.6 [2.0–4.6]</p></td><td align="left"><p>3.1 [2.0–4.3]</p></td><td align="left"><p>3.7 [2.5–6.8]</p></td><td char="." align="char"><p>0.03</p></td></tr><tr><td align="left"><p> H<sub>LF</sub> supine</p></td><td align="left"><p>3.9 [2.8–6.6]</p></td><td align="left"><p>5.1 [3.5–6.8]</p></td><td align="left"><p>8.2 [5.8–10.5]</p></td><td char="." align="char"><p>0.01</p></td></tr><tr><td align="left"><p> H<sub>LF</sub> standing</p></td><td align="left"><p>2.0 [1.6–4.0]</p></td><td align="left"><p>2.2 [1.5–3.3]</p></td><td align="left"><p>3.1 [1.9–4.8]</p></td><td char="." align="char"><p>0.07</p></td></tr><tr><td align="left"><p><bold>BRS</bold><sub><bold>SEQ</bold></sub> supine</p></td><td align="left"><p>6.7 [4.2–7.6]</p></td><td align="left"><p>7.2 [3.3–9]</p></td><td align="left"><p>9.3 [8–12.6]</p></td><td char="." align="char"><p>0.29</p></td></tr><tr><td align="left"><p><bold>BRS</bold><sub><bold>SEQ</bold></sub> standing</p></td><td align="left"><p>3.9 [2.3–5.3]</p></td><td align="left"><p>3.4 [3.2–4.5]</p></td><td align="left"><p>3.9 [2.4–5]</p></td><td char="." align="char"><p>0.08</p></td></tr><tr><td align="left" colspan="5"><p>Baroreflex resonance, mmHg<sup>2</sup></p></td></tr><tr><td align="left"><p><bold> SBP</bold><sub><bold>LF</bold></sub> supine</p></td><td align="left"><p>7.8 [3.9–14.2]</p></td><td align="left"><p>9.3 [4.7–11.7]</p></td><td align="left"><p>2.8 [2.1–3.8]</p></td><td char="." align="char"><p> < 0.01</p></td></tr><tr><td align="left"><p><bold> SBP</bold><sub><bold>LF</bold></sub> standing</p></td><td align="left"><p>14.6 [11.2–20.4]</p></td><td align="left"><p>17.0 [10.9–21.4]</p></td><td align="left"><p>5.8 [4.2–9.8]</p></td><td char="." align="char"><p> < 0.01</p></td></tr><tr><td align="left"><p><bold> DBP</bold><sub><bold>LF</bold></sub> supine</p></td><td align="left"><p>2.7 [1.9–5.3]</p></td><td align="left"><p>3.5 [1.8–5.8]</p></td><td align="left"><p>1.3 [1.1–2.0]</p></td><td char="." align="char"><p> < 0.01</p></td></tr><tr><td align="left"><p><bold> DBP</bold><sub><bold>LF</bold></sub> standing</p></td><td align="left"><p>5.0 [3.8–9.2]</p></td><td align="left"><p>5.9 [4.1–9.4]</p></td><td align="left"><p>2.4 [1.7–3.4]</p></td><td char="." align="char"><p> < 0.01</p></td></tr></tbody></table> </ephtml> </p> <p>BRS: baroreflex sensitivity; SBP = systolic blood pressure; DBP = diastolic blood pressure; LF = low frequency; HLF = BRS estimation by transfer function technique in LF band and α<subs>LF</subs> = BRS estimation by spectral method in LF band (for further details, see methods). Data are expressed as percentage or median [interquartile]. <emph>P</emph> values compare placebo versus reb-oxy. <emph>P</emph>-values are calculated by comparing the percent changes from baseline observed after placebo versus reb-oxy.</p> <p>Graph: Figure 1 Baroreflex sensitivity by the spectral method. αLF percent change (left) and HLF percent change (right) from baseline under placebo (white bar) and reb-oxy (grey bar) in supine and standing positions. Data are shown as medians (median absolute deviation); the * indicates statistical significance between reb-oxy and placebo. See Table 4 for the original values.</p> <p>Graph: Figure 2 Baroreflex sensitivity by the sequence method. BRSSEQ percent change from baseline under placebo (white bar) and reb-oxy (grey bar) in supine and standing positions. Data are shown as medians (standard error). See Table 4 for the original values. BRSSEQ percent change from baseline under placebo (white bar) and reb-oxy (grey bar) in supine and standing positions. Data are shown as medians (median absolute deviation).</p> <p>Regarding the baroreflex resonance in BP spectral powers, SBP<subs>LF</subs> and DBP<subs>LF</subs> were significantly and substantially lower after reb-oxy treatment than on placebo in both postures (Table 1 and Figure 3). The percent changes in SBP<subs>LF</subs> from supine to standing were similar on placebo (− 86% [− 204 to − 28]) and on reb-oxy (− 108.1% [− 266 to − 35], <emph>p</emph> = 0.60). This was the case also for the percent changes in DBP<subs>LF</subs> from supine to standing (placebo: − 101% [− 153 to − 31] %; reb-oxy: − 72% [− 101 to − 43] %, <emph>p</emph> 0.52).</p> <p>Graph: Figure 3 Baroreflex resonance. Percent changes of spectral powers in the low-frequency band for systolic (SBPLF, left) and diastolic (DBPLF, right) blood pressure from baseline in placebo (white bar) and reb-oxy (grey bar) in the supine and standing positions separately: data as medians (median absolute deviation). See Table 4 for the original values. The symbol * indicates statistical significance between reb-oxy and placebo.</p> <p>Reb-oxy did not induce orthostatic hypotension nor any modification of parasympathetic activity indices. The respiratory frequencies remained in the HF band in all treatment groups.</p> <hd id="AN0162057377-14">Discussion</hd> <p>We recently demonstrated that one-week bedtime administration of reboxetine plus oxybutynin reduces OSA severity[<reflink idref="bib23" id="ref41">23</reflink>]. Here, we add that, in OSA patients, this treatment is not associated with short-term autonomic dysregulation. Particularly, during indirect evaluations, the tested drug combination does not induce either sympathetic overactivity or orthostatic hypotension as it could be expected by the reboxetine mechanism of action.</p> <p>Our results show that one-week administration of reboxetine plus oxybutynin: (i) did not increase BP during the day or the night; (ii) did not enhance cardiac sympathetic modulation as reflected by nighttime HRV; (iii) did not impair but rather increased the sensitivity of the baroreflex control of heart rate; and (iv) decreased the baroreflex resonance in BP spectra, a surrogate measure for the vascular sympathetic modulation. To date, this is the first evaluation of the impact of the new OSA pharmacologic therapy on cardiovascular autonomic regulation.</p> <p>Reboxetine is highly selective for norepinephrine transporters and has a low affinity with muscarinic, histamine-H1, and adrenergic α1 receptors[<reflink idref="bib36" id="ref42">36</reflink>]. Reboxetine is prescribed for major depressive diseases, dysthymia, and attention-deficit/hyperactivity disorder, its antidepressant effects being related to the sustained increase in norepinephrine levels in the central nervous system[<reflink idref="bib37" id="ref43">37</reflink>]. As a noradrenergic drug, reboxetine would be expected to increase sympathetic activity. In fact, in previous studies on healthy volunteers, 4 mg of reboxetine has been associated with an increase in HR[<reflink idref="bib38" id="ref44">38</reflink>],[<reflink idref="bib39" id="ref45">39</reflink>]. Oxybutynin is an anticholinergic drug used for bladder over-activity. Its effect on muscarinic cardiac receptors determines inhibition of vagal activity with an increase in HR[<reflink idref="bib40" id="ref46">40</reflink>]. HR is indeed primarily modulated by the opposing autonomic influences of parasympathetic and sympathetic activity. Thus, theoretically, the administration of this drug combination would be expected to inhibit cardiac parasympathetic stimulation together with a direct sympathomimetic effect.</p> <hd id="AN0162057377-15">Reb-oxy and HR/BP levels in OSA</hd> <p>A previous pharmacological trial for OSA treatment showed that a single-night administration of atomoxetine plus oxybutynin in OSA patients led to a small (2.6 bpm) overnight increase in HR[<reflink idref="bib22" id="ref47">22</reflink>]. Similarly, in our study, HR during the night only slightly increased (by 3.7 bpm) on reb-oxy versus placebo during PSG. Moreover, the 24 h HR evaluated during the ABPM was similar in the two groups. Previous studies in healthy subjects reported an increase in SBP and DBP after reboxetine administration[<reflink idref="bib38" id="ref48">38</reflink>],[<reflink idref="bib39" id="ref49">39</reflink>],[<reflink idref="bib41" id="ref50">41</reflink>], whereas neutral effects on BP have been reported in long-term treatment with reboxetine[<reflink idref="bib37" id="ref51">37</reflink>],[<reflink idref="bib42" id="ref52">42</reflink>],[<reflink idref="bib43" id="ref53">43</reflink>]. In our patients, BP did not differ between placebo and reb-oxy and we did not observe orthostatic hypotension after 1 week of reb-oxy administration, confirming the neutral effect previously reported even in a population of OSA patients. Morning surge and BP variability, additional markers of sympathetic activity, did not increase during reb-oxy administration, which, again, represents a reassuring clinical result considering the administration of a noradrenergic drug.</p> <hd id="AN0162057377-16">Reb-oxy and HRV in OSA</hd> <p>Using HRV analysis, OSA patients were shown to be characterized by a predominance of sympathetic markers and by a reduction in parasympathetic indices[<reflink idref="bib44" id="ref54">44</reflink>]–[<reflink idref="bib46" id="ref55">46</reflink>]. This is in line with the demonstration that sympathetic overactivity is a key mediator of adverse cardiovascular consequences in OSA[<reflink idref="bib47" id="ref56">47</reflink>]. In fact, autonomic derangement and sympathovagal imbalance are associated with arrhythmias, which are often observed in patients with OSA, contributing to their cardiovascular mortality[<reflink idref="bib48" id="ref57">48</reflink>]. Previous studies showed that reboxetine influences the autonomic nervous system by reducing the HF power of HRV in healthy volunteers[<reflink idref="bib39" id="ref58">39</reflink>]. Oxybutynin, in turn, showed an anti-cholinergic effect according to HRV indexes[<reflink idref="bib40" id="ref59">40</reflink>]. By contrast, our study points out that in OSA patients one week of reb-oxy did not increase sympathetic activity, as shown by no changes in the HRV spectral index of sympathovagal balance, i.e., the LF/HF power ratio, and had no significant influence on HRV indexes of parasympathetic cardiac control: RMSSD, pNN50, and the HF power.</p> <hd id="AN0162057377-17">Reb-oxy and arterial baroreflex cardiovascular modulation in OSA</hd> <p>An unbalanced cardiac baroreflex modulation has been shown to favor cardiovascular complications and arrhythmias. Particularly, in OSA patients the known reduction in BRS during both wake and sleep is associated with the development of arterial hypertension and with excessive daytime sleepiness[<reflink idref="bib24" id="ref60">24</reflink>],[<reflink idref="bib49" id="ref61">49</reflink>]. Our study does not report any worsening of BRS after reb-oxy treatment, as it could be theoretically expected considering the autonomic effects of the noradrenergic reboxetine and anticholinergic oxybutynin. On the contrary, our data show a significantly improved sensitivity of arterial baroreflex modulation of HR, in particular in the LF band (α<subs>LF</subs> and H<subs>LF</subs>). It has been shown that α<subs>LF</subs> and H<subs>LF</subs> reflect baroreflex modulation of HR through both the sympathetic and the parasympathetic neural influences. Conversely, BRS<subs>SEQ</subs> mainly reflects the vagal HR modulation[<reflink idref="bib50" id="ref62">50</reflink>]. Thus, our findings of increased α<subs>LF</subs> and H<subs>LF</subs> accompanied by no changes in BRS<subs>SEQ</subs> suggest that one-week treatment with reb-oxy improved BRS mainly through a reduction of cardiac sympathetic modulation, with no evident changes in vagal control of HR.</p> <p>Moreover, our study demonstrates that reb-oxy largely decreased the power of SBP and DBP oscillations at LF, which have been suggested to be an expression of the resonance in the baroreflex loop at a frequency of 0.1 Hz, considered a surrogate measure for sympathetic vascular regulation. Thus, when considering all the above findings, our study suggests the occurrence of a reduction in the overactivity of sympathetic cardiovascular control induced by sleep apneas in OSA patients after one week of reb-oxy treatment. This reduction, however, was not accompanied by major alterations in posture-induced changes in cardiovascular control, as demonstrated by the lack of orthostatic hypotension and other signs of autonomic imbalance.</p> <p>The improvement in baroreflex cardiac modulation we observed during wake is likely to represent a positive consequence of nocturnal apneas reduction, as previously reported after long-term OSA treatment with CPAP[<reflink idref="bib12" id="ref63">12</reflink>]. Thus, similarly to what happens with CPAP treatment, it might be supposed that the beneficial effect of drug combination on the severity of OSA would have mitigated the sympathetic hyperactivity induced by OSA events[<reflink idref="bib9" id="ref64">9</reflink>],[<reflink idref="bib12" id="ref65">12</reflink>],[<reflink idref="bib51" id="ref66">51</reflink>]. The reduction of the hypoxic burden, together with a reduced frequency of arousals from sleep determined by reb-oxy, might have determined the beneficial effect on the apnea-hypopnea-related sympathetic overflow[<reflink idref="bib52" id="ref67">52</reflink>],[<reflink idref="bib53" id="ref68">53</reflink>].</p> <hd id="AN0162057377-18">Limitations</hd> <p>Even if the present study offers unique data on the effects of a novel drug treatment for OSA over the longest administration period tested so far, we acknowledge a few limitations. First, our findings on the short-term impact of Reb-Oxy on cardiac autonomic modulation in OSA patients cannot be generalize to other populations and need to be confirmed over a longer period. Second, the relatively small sample size was powered to detect significant changes in AHI, not in baroreflex or HRV indices, possibly precluding the detection of smaller effects of the treatment. Third, by study design we evaluated cardiovascular autonomic modulations only by indirect measures, as direct measures of sympathetic activity such as norepinephrine spillover or muscle sympathetic nerve traffic were excluded.</p> <hd id="AN0162057377-19">Conclusions</hd> <p>We demonstrate for the first time that the combination of the noradrenergic drug reboxetine and the anticholinergic drug oxybutynin could safely be administrated in OSA patients, who are typically characterized by sympathetic overactivity due to sleep apnea <emph>per se</emph>. Being efficacious on OSA severity, these drugs could also positively act to improve the deranged cardiovascular autonomic modulation typical of OSA. Future intervention trials, including a larger number of OSA patients followed over longer treatment periods are needed to assess whether these favorable clinical and pathophysiological effects are also associated with a reduction in cardiovascular morbidity and mortality.</p> <hd id="AN0162057377-20">Author contributions</hd> <p>E.P., C.L., and G.P. contributed to study design, E.P., D.R., S.V. contributed to study execution. E.P., P.C., D.S., A.Z., A.F., C.L., P.M., S.C and C.B contributed to data analysis. E.P. and L.P. contributed to drafting of the manuscript. P.C., D.S., P.M., A.A., S.C, C.B. and A.F. contributed to revision and G.P., P.C. and C.L. contributed to final drafting of the manuscript.</p> <hd id="AN0162057377-21">Funding</hd> <p>Apnimed Inc. (20 Holyoke St, Cambridge, MA 02138) financially supported the realization of the study and partially supported by the Italian Ministry of Health.</p> <hd id="AN0162057377-22">Data availability</hd> <p>Data used for this study are available from the corresponding author upon reasonable request.</p> <hd id="AN0162057377-23">Competing interests</hd> <p>E.P., P.C., D.S., A.Z., D.R., S.V., A.F., P.M., L.P., S.C, C.B., C.L., and G.P. have no conflict of interest related to the current project. A.A. served as consultant for Somnifix, Apnimed, Inspire, and LinguaFlex and reports grants from Somnifix, outside the current work.</p> <hd id="AN0162057377-24">Supplementary Information</hd> <p>Graph: Supplementary Information.</p> <hd id="AN0162057377-25">Supplementary Information</hd> <p>The online version contains supplementary material available at https://doi.org/10.1038/s41598-023-29436-9.</p> <hd id="AN0162057377-26">Publisher's note</hd> <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p> <ref id="AN0162057377-27"> <title> References </title> <blist> <bibl id="bib1" idref="ref1" type="bt">1</bibl> <bibtext> Benjafield AV. Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. Lancet Respir. Med. 2019; 7: 687-698. 10.1016/s2213-2600(19)30198-5. 31300334. 7007763</bibtext> </blist> <blist> <bibl id="bib2" idref="ref2" type="bt">2</bibl> <bibtext> Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 1995; 96: 1897-1904. 1:CAS:528:DyaK2MXosFyhtrc%3D. 10.1172/jci118235. 7560081. 185826</bibtext> </blist> <blist> <bibl id="bib3" idref="ref3" type="bt">3</bibl> <bibtext> Nieto FJ. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000; 283: 1829-1836. 1:STN:280:DC%2BD3c3jtV2isQ%3D%3D. 10.1001/jama.283.14.1829. 10770144</bibtext> </blist> <blist> <bibl id="bib4" idref="ref5" type="bt">4</bibl> <bibtext> Sánchez-de-la-Torre M, Campos-Rodriguez F, Barbé F. Obstructive sleep apnoea and cardiovascular disease. Lancet Respir. Med. 2013; 1: 61-72. 10.1016/s2213-2600(12)70051-6. 24321805</bibtext> </blist> <blist> <bibl id="bib5" idref="ref6" type="bt">5</bibl> <bibtext> Shahar E. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2001; 163: 19-25. 1:STN:280:DC%2BD3MzgtVygsw%3D%3D. 10.1164/ajrccm.163.1.2001008. 11208620</bibtext> </blist> <blist> <bibl id="bib6" idref="ref7" type="bt">6</bibl> <bibtext> Somers VK. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008; 118: 1080-1111. 10.1161/circulationaha.107.189375. 18725495</bibtext> </blist> <blist> <bibl id="bib7" idref="ref8" type="bt">7</bibl> <bibtext> Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet. 2005; 365: 1046-1053. 10.1016/S0140-6736(05)71141-7. 15781100</bibtext> </blist> <blist> <bibl id="bib8" idref="ref9" type="bt">8</bibl> <bibtext> Roche F. Reduced cardiac sympathetic autonomic tone after long-term nasal continuous positive airway pressure in obstructive sleep apnoea syndrome. Clin. Physiol. 1999; 19: 127-134. 1:STN:280:DyaK1M3hs12msw%3D%3D. 10.1046/j.1365-2281.1999.00163.x. 10200894</bibtext> </blist> <blist> <bibl id="bib9" idref="ref10" type="bt">9</bibl> <bibtext> Bonsignore MR. Baroreflex control of heart rate during sleep in severe obstructive sleep apnoea: Effects of acute CPAP. Eur. Respir. J. 2006; 27: 128-135. 1:STN:280:DC%2BD28%2FgtFensg%3D%3D. 10.1183/09031936.06.00042904. 16387945</bibtext> </blist> <blist> <bibtext> Parati G. Autonomic cardiac regulation in obstructive sleep apnea syndrome: Evidence from spontaneous baroreflex analysis during sleep. J. Hypertens. 1997; 15: 1621-1626. 1:STN:280:DyaK1c7kslGgtQ%3D%3D. 10.1097/00004872-199715120-00063. 9488213</bibtext> </blist> <blist> <bibtext> Parati G. Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension. 1988; 12: 214-222. 1:STN:280:DyaL1czhsVagtw%3D%3D. 10.1161/01.hyp.12.2.214. 3410530</bibtext> </blist> <blist> <bibtext> Bonsignore MR. Continuous positive airway pressure treatment improves baroreflex control of heart rate during sleep in severe obstructive sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 2002; 166: 279-286. 10.1164/rccm.2107117. 12153958</bibtext> </blist> <blist> <bibtext> Archbold KH, Parthasarathy S. Adherence to positive airway pressure therapy in adults and children. Curr. Opin. Pulm. Med. 2009; 15: 585-590. 10.1097/MCP.0b013e3283319b3f. 19713846</bibtext> </blist> <blist> <bibtext> Rapelli G. Improving CPAP adherence in adults with obstructive sleep apnea syndrome: A scoping review of motivational interventions. Front Psychol. 2021; 12: 705364. 10.3389/fpsyg.2021.705364. 34475840. 8406627</bibtext> </blist> <blist> <bibtext> Perger E, Jutant EM, Redolfi S. Targeting volume overload and overnight rostral fluid shift: A new perspective to treat sleep apnea. Sleep Med. Rev. 2018; 42: 160-170. 10.1016/j.smrv.2018.07.008. 30177246</bibtext> </blist> <blist> <bibtext> Taranto-Montemurro L, Messineo L, Wellman A. Targeting endotypic traits with medications for the pharmacological treatment of obstructive sleep apnea. A review of the current literature. J. Clin. Med. 2019; 8: 1. 1:CAS:528:DC%2BB3cXmsl2ntL0%3D. 10.3390/jcm8111846</bibtext> </blist> <blist> <bibtext> Perger E, Taranto-Montemurro L. Upper airway muscles: Influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options. Curr. Opin. Pulm. Med. 2021. 10.1097/mcp.0000000000000818. 34431788</bibtext> </blist> <blist> <bibtext> Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am. J. Respir. Crit. Care Med. 2013; 188: 996-1004. 10.1164/rccm.201303-0448OC. 23721582. 3826282</bibtext> </blist> <blist> <bibtext> Pini L. Phenotyping OSAH patients during wakefulness. Sleep Breath. 2022. 10.1007/s11325-021-02551-5. 35023036</bibtext> </blist> <blist> <bibtext> Chan E, Steenland HW, Liu H, Horner RL. Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states. Am. J. Respir. Crit. Care Med. 2006; 174: 1264-1273. 1:CAS:528:DC%2BD28XhtlCktb7O. 10.1164/rccm.200605-597OC. 16931636</bibtext> </blist> <blist> <bibtext> Grace KP, Hughes SW, Horner RL. Identification of the mechanism mediating genioglossus muscle suppression in REM sleep. Am. J. Respir. Crit. Care Med. 2013; 187: 311-319. 10.1164/rccm.201209-1654OC. 23220910</bibtext> </blist> <blist> <bibtext> Taranto-Montemurro L. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am. J. Respir. Crit. Care Med. 2019; 199: 1267-1276. 1:CAS:528:DC%2BC1MXhsFKgu7rJ. 10.1164/rccm.201808-1493OC. 30395486. 6519859</bibtext> </blist> <blist> <bibtext> Perger E. Reboxetine plus oxybutynin for obstructed sleep apnea treatment A 1-week randomized, placebo-controlled, double-blind crossover trial. Chest. 2021. 10.1016/j.chest.2021.08.080. 34543665</bibtext> </blist> <blist> <bibtext> Cortelli P, Lombardi C, Montagna P, Parati G. Baroreflex modulation during sleep and in obstructive sleep apnea syndrome. Auton. Neurosci. 2012; 169: 7-11. 1:STN:280:DC%2BC38rht1Wnsg%3D%3D. 10.1016/j.autneu.2012.02.005. 22465134</bibtext> </blist> <blist> <bibtext> Tank J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003; 107: 2949-2954. 10.1161/01.CIR.0000072786.99163.FE. 12796139</bibtext> </blist> <blist> <bibtext> Parati G, Mancia G, Di Rienzo M, Castiglioni P. Point: Cardiovascular variability is/is not an index of autonomic control of circulation. J. Appl. Physiol. (1985). 2006; 101: 676-678. 10.1152/japplphysiol.00446.2006. 16645191discussion 681–672</bibtext> </blist> <blist> <bibtext> La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: Measurement and clinical implications. Ann. Noninvasive Electrocardiol. 2008; 13: 191-207. 10.1111/j.1542-474X.2008.00219.x. 18426445. 6931942</bibtext> </blist> <blist> <bibtext> Electrophysiology, T. F. o. t. E. S. o. C. t. N. A. S. o. P. Heart rate variability. Circulation93, 1043–1065, https://doi.org/10.1161/01.CIR.93.5.1043 (1996).</bibtext> </blist> <blist> <bibtext> Sateia MJ. International classification of sleep disorders-third edition: Highlights and modifications. Chest. 2014; 146: 1387-1394. 10.1378/chest.14-0970. 25367475</bibtext> </blist> <blist> <bibtext> Rosenberg RS, Van Hout S. The American academy of sleep medicine inter-scorer reliability program: Respiratory events. J. Clin. Sleep Med. 2014; 10: 447-454. 10.5664/jcsm.3630. 24733993. 3960390</bibtext> </blist> <blist> <bibtext> Moody, G. B. et al.Clinical Validation of the ECG-Derived Respiration (EDR) Technique; Computers in Cardiology, vol. 13, pp. 507–510 (Washington, DC: IEEE Computer Society Press, 1986).</bibtext> </blist> <blist> <bibtext> Parati G. Arterial baroreflex control of heart rate: Determining factors and methods to assess its spontaneous modulation. J. Physiol. 2005; 565: 706-707. 1:CAS:528:DC%2BD2MXlslChsrk%3D. 10.1113/jphysiol.2005.086827. 15878943. 1464559</bibtext> </blist> <blist> <bibtext> Robbe HW. Assessment of baroreceptor reflex sensitivity by means of spectral analysis. Hypertension. 1987; 10: 538-543. 1:STN:280:DyaL1c%2FjtFGksA%3D%3D. 10.1161/01.HYP.10.5.538. 3666866</bibtext> </blist> <blist> <bibtext> Pagani M. Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension. 1988; 12: 600-610. 1:STN:280:DyaL1M%2FnvFaltw%3D%3D. 10.1161/01.HYP.12.6.600. 3203964</bibtext> </blist> <blist> <bibtext> Julien C. The enigma of Mayer waves: Facts and models. Cardiovasc. Res. 2006; 70: 12-21. 1:CAS:528:DC%2BD28XivVejsbg%3D. 10.1016/j.cardiores.2005.11.008. 16360130</bibtext> </blist> <blist> <bibtext> Wong EH. Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psych. 2000; 47: 818-829. 1:CAS:528:DC%2BD3cXjt1aru7s%3D. 10.1016/s0006-3223(99)00291-7</bibtext> </blist> <blist> <bibtext> Fossa AA. Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine. Toxicol Appl. Pharmacol. 2012; 264: 343-350. 1:CAS:528:DC%2BC38XhsFClu7rL. 10.1016/j.taap.2012.09.010. 23000177</bibtext> </blist> <blist> <bibtext> Schroeder C. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002; 105: 347-353. 1:CAS:528:DC%2BD38XhsFSgurc%3D. 10.1161/hc0302.102597. 11804991</bibtext> </blist> <blist> <bibtext> Penttilä J, Syvälahti E, Hinkka S, Kuusela T, Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. Psychopharmacology. 2001; 154: 343-349. 10.1007/s002130000664. 11349386</bibtext> </blist> <blist> <bibtext> Akbari E, Zare AH, Alipour A. The effect of oxybutynin on cardiac autonomic modulation in healthy subjects. Clin. Auton. Res. 2014; 24: 167-174. 10.1007/s10286-014-0247-9. 24928796</bibtext> </blist> <blist> <bibtext> Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I. Hemodynamic effects of reboxetine in healthy male volunteers. Clin. Pharmacol. Ther. 1999; 66: 282-287. 1:CAS:528:DyaK1MXmsFOjtLg%3D. 10.1016/s0009-9236(99)70036-6. 10511064</bibtext> </blist> <blist> <bibtext> Riahi F, Tashakori A, Izadi-Mazidi S, Salehi-Veysi M. Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders. Iran J. Psych. 2013; 8: 195-200</bibtext> </blist> <blist> <bibtext> Agelink MW, Ullrich H, Baumann B, Strum S, Majewski T. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: Preliminary data. Psychopharmacology. 2002; 163: 151-156. 1:CAS:528:DC%2BD38XosVGrt7s%3D. 10.1007/s00213-002-1146-7. 12202961</bibtext> </blist> <blist> <bibtext> Sequeira VCC, Bandeira PM, Azevedo JCM. Heart rate variability in adults with obstructive sleep apnea: A systematic review. Sleep Sci. 2019; 12: 214-221. 10.5935/1984-0063.20190082. 31890098. 6932836</bibtext> </blist> <blist> <bibtext> Taranto-Montemurro L. Cardiac sympathetic hyperactivity in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. COPD. 2016; 13: 706-711. 10.1080/15412555.2016.1199668. 27383268</bibtext> </blist> <blist> <bibtext> Vena D. Heart rate variability responses of individuals with and without saline-induced obstructive sleep apnea. J. Clin. Sleep Med. 2018; 14: 503-510. 10.5664/jcsm.7032. 29609720. 5886427</bibtext> </blist> <blist> <bibtext> Javaheri S. Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences. J. Am. Coll. Cardiol. 2017; 69: 841-858. 10.1016/j.jacc.2016.11.069. 28209226. 5393905</bibtext> </blist> <blist> <bibtext> May AM, Van Wagoner DR, Mehra R. OSA and cardiac arrhythmogenesis: Mechanistic insights. Chest. 2017; 151: 225-241. 10.1016/j.chest.2016.09.014. 27693594</bibtext> </blist> <blist> <bibtext> Lombardi C. Daytime sleepiness and neural cardiac modulation in sleep-related breathing disorders. J. Sleep Res. 2008; 17: 263-270. 10.1111/j.1365-2869.2008.00659.x. 18503513</bibtext> </blist> <blist> <bibtext> Silva LEV, Dias DPM, da Silva CAA, Salgado HC, Fazan R. Revisiting the sequence method for baroreflex analysis. Front. Neurosci. 2019; 1: 3. 10.3389/fnins.2019.00017</bibtext> </blist> <blist> <bibtext> Narkiewicz K. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999; 100: 2332-2335. 1:STN:280:DC%2BD3c%2FlsVWgsQ%3D%3D. 10.1161/01.cir.100.23.2332. 10587337</bibtext> </blist> <blist> <bibtext> Ferreira CB, Schoorlemmer GH, Rocha AA, Cravo SL. Increased sympathetic responses induced by chronic obstructive sleep apnea are caused by sleep fragmentation. J. Appl. Physiol. 2020; 129: 163-172. 1:CAS:528:DC%2BB3cXhvFOlurrM. 10.1152/japplphysiol.00811.2019. 32552428</bibtext> </blist> <blist> <bibtext> Azarbarzin A. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: The osteoporotic fractures in men study and the sleep heart health study. Eur. Heart J. 2019; 40: 1149-1157. 10.1093/eurheartj/ehy624. 30376054</bibtext> </blist> </ref> <aug> <p>By Elisa Perger; Paolo Castiglioni; Andrea Faini; Davide Soranna; Antonella Zambon; Debora Rosa; Stefano Vicini; Paolo Meriggi; Laura Pini; Claudia Baratto; Sergio Caravita; Ali Azarbarzin; Gianfranco Parati and Carolina Lombardi</p> <p>Reported by Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author</p> </aug> <nolink nlid="nl1" bibid="bib10" firstref="ref11"></nolink> <nolink nlid="nl2" bibid="bib12" firstref="ref12"></nolink> <nolink nlid="nl3" bibid="bib13" firstref="ref13"></nolink> <nolink nlid="nl4" bibid="bib14" firstref="ref14"></nolink> <nolink nlid="nl5" bibid="bib15" firstref="ref15"></nolink> <nolink nlid="nl6" bibid="bib17" firstref="ref16"></nolink> <nolink nlid="nl7" bibid="bib18" firstref="ref17"></nolink> <nolink nlid="nl8" bibid="bib19" firstref="ref18"></nolink> <nolink nlid="nl9" bibid="bib20" firstref="ref19"></nolink> <nolink nlid="nl10" bibid="bib21" firstref="ref20"></nolink> <nolink nlid="nl11" bibid="bib22" firstref="ref22"></nolink> <nolink nlid="nl12" bibid="bib23" firstref="ref23"></nolink> <nolink nlid="nl13" bibid="bib24" firstref="ref24"></nolink> <nolink nlid="nl14" bibid="bib25" firstref="ref25"></nolink> <nolink nlid="nl15" bibid="bib26" firstref="ref27"></nolink> <nolink nlid="nl16" bibid="bib28" firstref="ref28"></nolink> <nolink nlid="nl17" bibid="bib29" firstref="ref29"></nolink> <nolink nlid="nl18" bibid="bib30" firstref="ref30"></nolink> <nolink nlid="nl19" bibid="bib31" firstref="ref33"></nolink> <nolink nlid="nl20" bibid="bib32" firstref="ref34"></nolink> <nolink nlid="nl21" bibid="bib33" firstref="ref35"></nolink> <nolink nlid="nl22" bibid="bib34" firstref="ref36"></nolink> <nolink nlid="nl23" bibid="bib35" firstref="ref37"></nolink> <nolink nlid="nl24" bibid="bib36" firstref="ref42"></nolink> <nolink nlid="nl25" bibid="bib37" firstref="ref43"></nolink> <nolink nlid="nl26" bibid="bib38" firstref="ref44"></nolink> <nolink nlid="nl27" bibid="bib39" firstref="ref45"></nolink> <nolink nlid="nl28" bibid="bib40" firstref="ref46"></nolink> <nolink nlid="nl29" bibid="bib41" firstref="ref50"></nolink> <nolink nlid="nl30" bibid="bib42" firstref="ref52"></nolink> <nolink nlid="nl31" bibid="bib43" firstref="ref53"></nolink> <nolink nlid="nl32" bibid="bib44" firstref="ref54"></nolink> <nolink nlid="nl33" bibid="bib46" firstref="ref55"></nolink> <nolink nlid="nl34" bibid="bib47" firstref="ref56"></nolink> <nolink nlid="nl35" bibid="bib48" firstref="ref57"></nolink> <nolink nlid="nl36" bibid="bib49" firstref="ref61"></nolink> <nolink nlid="nl37" bibid="bib50" firstref="ref62"></nolink> <nolink nlid="nl38" bibid="bib51" firstref="ref66"></nolink> <nolink nlid="nl39" bibid="bib52" firstref="ref67"></nolink> <nolink nlid="nl40" bibid="bib53" firstref="ref68"></nolink>
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=20452322&ISBN=&volume=13&issue=1&date=20230201&spage=1&pages=1-1&title=Scientific Reports&atitle=Author%20Correction%3A%20Direct%20and%20high%20throughput%20%28HT%29%20interactions%20on%20the%20ribosomal%20surface%20by%20iRIA&aulast=Elisa%20Pesce&id=DOI:10.1038/s41598-023-28876-7
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/f52f929a627d42f39e9074a05ba066f6
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.f52f929a627d42f39e9074a05ba066f6
RelevancyScore: 936
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 935.989685058594
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Author Correction: Direct and high throughput (HT) interactions on the ribosomal surface by iRIA
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Elisa+Pesce%22">Elisa Pesce</searchLink><br /><searchLink fieldCode="AR" term="%22Claudia+Minici%22">Claudia Minici</searchLink><br /><searchLink fieldCode="AR" term="%22Jochen+Baßler%22">Jochen Baßler</searchLink><br /><searchLink fieldCode="AR" term="%22Ed+Hurt%22">Ed Hurt</searchLink><br /><searchLink fieldCode="AR" term="%22Massimo+Degano%22">Massimo Degano</searchLink><br /><searchLink fieldCode="AR" term="%22Piera+Calamita%22">Piera Calamita</searchLink><br /><searchLink fieldCode="AR" term="%22Stefano+Biffo%22">Stefano Biffo</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Nature Portfolio, 2023.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2023
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Medicine<br />LCC:Science
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Science%22">Science</searchLink>
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2045-2322
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://doaj.org/toc/2045-2322
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1038/s41598-023-28876-7
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/f52f929a627d42f39e9074a05ba066f6" linkWindow="_blank">https://doaj.org/article/f52f929a627d42f39e9074a05ba066f6</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.f52f929a627d42f39e9074a05ba066f6
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.f52f929a627d42f39e9074a05ba066f6
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41598-023-28876-7
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: 1
    Subjects:
      – SubjectFull: Medicine
        Type: general
      – SubjectFull: Science
        Type: general
    Titles:
      – TitleFull: Author Correction: Direct and high throughput (HT) interactions on the ribosomal surface by iRIA
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Elisa Pesce
      – PersonEntity:
          Name:
            NameFull: Claudia Minici
      – PersonEntity:
          Name:
            NameFull: Jochen Baßler
      – PersonEntity:
          Name:
            NameFull: Ed Hurt
      – PersonEntity:
          Name:
            NameFull: Massimo Degano
      – PersonEntity:
          Name:
            NameFull: Piera Calamita
      – PersonEntity:
          Name:
            NameFull: Stefano Biffo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 20452322
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Scientific Reports
              Type: main
ResultId 1